HK1252415A1 - 包含3-(5-氨基-2-甲基-4-氧代基-4h-喹唑啉-3-基)-呱啶-2，6-二酮的藥物組合物 - Google Patents

包含3-(5-氨基-2-甲基-4-氧代基-4h-喹唑啉-3-基)-呱啶-2，6-二酮的藥物組合物

Info

Publication number
HK1252415A1
HK1252415A1 HK18111712.4A HK18111712A HK1252415A1 HK 1252415 A1 HK1252415 A1 HK 1252415A1 HK 18111712 A HK18111712 A HK 18111712A HK 1252415 A1 HK1252415 A1 HK 1252415A1
Authority
HK
Hong Kong
Prior art keywords
quinazolin
dione
piperidine
oxo
amino
Prior art date
Application number
HK18111712.4A
Other languages
English (en)
Inventor
科林‧沃爾特斯
威廉‧鮑恩
孫亞麗
傑伊‧布魯姆菲爾德
沈曉軒
鄒道忠
英德拉吉特‧高希
Original Assignee
細胞基因公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 細胞基因公司 filed Critical 細胞基因公司
Publication of HK1252415A1 publication Critical patent/HK1252415A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
HK18111712.4A 2015-08-27 2018-09-12 包含3-(5-氨基-2-甲基-4-氧代基-4h-喹唑啉-3-基)-呱啶-2，6-二酮的藥物組合物 HK1252415A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210923P 2015-08-27 2015-08-27

Publications (1)

Publication Number Publication Date
HK1252415A1 true HK1252415A1 (zh) 2019-05-24

Family

ID=56883865

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111712.4A HK1252415A1 (zh) 2015-08-27 2018-09-12 包含3-(5-氨基-2-甲基-4-氧代基-4h-喹唑啉-3-基)-呱啶-2，6-二酮的藥物組合物

Country Status (17)

Country Link
US (1) US10064863B2 (zh)
EP (1) EP3340969B1 (zh)
JP (1) JP2018525422A (zh)
KR (1) KR20180039084A (zh)
CN (1) CN107921004A (zh)
AU (1) AU2016310340A1 (zh)
BR (1) BR112018003335A2 (zh)
CA (1) CA2996641A1 (zh)
CL (1) CL2018000489A1 (zh)
CO (1) CO2018002545A2 (zh)
EA (1) EA201890585A1 (zh)
EC (1) ECSP18023544A (zh)
ES (1) ES2865289T3 (zh)
HK (1) HK1252415A1 (zh)
IL (1) IL257666A (zh)
MX (1) MX2018002487A (zh)
WO (1) WO2017035443A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
US10159675B2 (en) 2015-12-02 2018-12-25 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
DK2420497T3 (en) 2006-09-26 2016-03-07 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
CA2829592A1 (en) * 2011-03-11 2012-09-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
MX2013010360A (es) * 2011-03-11 2014-04-14 Celgene Corp Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos.
AR099385A1 (es) * 2014-01-15 2016-07-20 Celgene Corp Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona

Also Published As

Publication number Publication date
CL2018000489A1 (es) 2018-08-03
US10064863B2 (en) 2018-09-04
BR112018003335A2 (pt) 2018-09-25
MX2018002487A (es) 2018-06-15
EA201890585A1 (ru) 2018-11-30
ECSP18023544A (es) 2018-04-30
EP3340969A1 (en) 2018-07-04
CA2996641A1 (en) 2017-03-02
CN107921004A (zh) 2018-04-17
US20170056323A1 (en) 2017-03-02
KR20180039084A (ko) 2018-04-17
WO2017035443A1 (en) 2017-03-02
CO2018002545A2 (es) 2018-07-10
JP2018525422A (ja) 2018-09-06
AU2016310340A1 (en) 2018-03-15
EP3340969B1 (en) 2021-02-17
IL257666A (en) 2018-04-30
ES2865289T3 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
ZA201702086B (en) Long acting pharmaceutical compositions
GB201608323D0 (en) Pharmaceutical compositions
HK1254573A1 (zh) 包含苯基氨基嘧啶衍生物的藥物組合物
GB201521462D0 (en) Pharmaceutical composition
HK1250491A1 (zh) 穩定化的醫藥組合物
IL259597A (en) Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
GB201515310D0 (en) Pharmaceutical composition
HK1245073A1 (zh) 藥物組合物
HK1252415A1 (zh) 包含3-(5-氨基-2-甲基-4-氧代基-4h-喹唑啉-3-基)-呱啶-2，6-二酮的藥物組合物
ZA201703114B (en) Long acting pharmaceutical compositions for hepatitis c
GB201520862D0 (en) Pharmaceutical composition
GB201611920D0 (en) Pharmaceutical compositions
ZA201701714B (en) Anthostema senegalense-based composition, for use as an anti-aids drug
PL3329939T3 (pl) Stała kompozycja farmaceutyczna nienadająca się do nadużywania
LT3389638T (lt) Farmacinė kompozicija, kurios sudėtyje yra pimobendano
GB201700831D0 (en) Pharmaceutical compositions
GB201608393D0 (en) Solid pharmaceutical compositions
PL3319596T3 (pl) Farmaceutyczne kompozycje
GB201520762D0 (en) Novel pharmaceutical compositions
GB201521456D0 (en) Pharmaceutical composition
GB201516183D0 (en) Novel pharmaceutical composition
GB201506598D0 (en) Pharmaceutical compositions
TH1501006617A (th) การสังเคราะห์ 3-(5อะมิโน-2-เมธิล-4-ออกโซควินาโซลิน-3(4h)-อิล)ไพเพอริดีน-2,6-ไดโอน